CADTH

Consultation on Extending the Time Frame for Releasing the Embargoed CDEC Recommendation

Call for Feedback Deadline: March 24, 2016 at 5:00 p.m. EST via email to feedback@cadth.ca

Purpose

CADTH is inviting stakeholder comments and feedback on the proposed extension of the time frame for releasing the embargoed CADTH Canadian Drug Expert Committee (CDEC) recommendation, which is currently five to seven business days, to eight to 10 business days after the CDEC meeting.

Background and Proposal

In accordance with section 8.2 of the current *Procedure for the CADTH Common Drug Review*, the embargoed CDEC recommendation is sent to the manufacturer and other authorized recipients (e.g., the drug plans that participate in Common Drug Review [CDR] process) five to seven business days after the CDEC meeting at which the recommendation was made. In recent years, the complexity of CDR submissions has generally increased (e.g., the addition of network meta-analyses); however, the time frame for releasing the embargoed CDEC recommendation has remained constant. This has created time constraints for CADTH staff and CDEC members to finalize the documentation in a relatively short period of time.

In order to maintain and improve the quality of CDEC recommendation documents, CADTH is proposing to increase the time frame for releasing the embargoed CDEC recommendation to eight to 10 business days after the CDEC meeting at which the recommendation was made. This will permit CADTH staff and CDEC members to have additional time to summarize the committee's interpretation of the evidence.

Table 1: Proposed Revision to the Procedure for Releasing the Embargoed CDEC Recommendation

Procedure	Current Procedure	Proposed Revised Procedure
Releasing Embargoed CDEC Recommendation (section 8.2 b)	The embargoed CDEC recommendation will be sent to the manufacturer and the drug plans within **five to seven business days** following the CDEC meeting at which the recommendation was made.	The embargoed CDEC recommendation will be sent to the manufacturer and the drug plans within **eight to 10 business days** following the CDEC meeting at which the recommendation was made.

How to Submit Your Feedback

- To provide feedback, you must identify yourself — feedback provided by individuals who do not identify themselves and the organization they represent will not be considered.
- Only one response per organization will be considered. If more than one response is received, only the first response received will be considered.
- Feedback *must* be provided in 11-point font and saved in one of the following formats:
  - Microsoft Word document (.doc or .docx)
  - Unlocked PDF document that permits copying and pasting of text.
- Feedback should be presented clearly and succinctly.
- The maximum length of feedback is one page per response to this consulation.

Next Steps

The final decision regarding the proposed revision to the CDR procedure will be made after careful assessment of stakeholder feedback generated from this consultation and communicated in a future *CDR Update*.